Sana Biotechnology (SANA) EBT (2020 - 2026)

Sana Biotechnology's EBT history runs 7 years deep, the most recent figure standing at -$47.7 million for Q1 2026.

• In Q1 2026, EBT rose 3.98% year-over-year to -$47.7 million; the TTM figure through Mar 2026 stood at -$244.5 million (down 19.73% YoY), while the FY2025 annual figure was -$246.5 million, up 6.02% from the prior year.
• EBT came in at -$47.7 million for Q1 2026 at Sana Biotechnology, up from -$59.9 million in the prior quarter.
• In the past five years, EBT ranged from a high of $681000.0 in Q3 2023 to a low of -$113.9 million in Q2 2023.
• A 5-year average of -$65.2 million and a median of -$59.9 million in 2025 frame the typical range for EBT.
• Across the five-year window, EBT surged 100.8% in 2023 and plunged 8790.46% in 2024, its largest moves.
• Sana Biotechnology's EBT stood at -$80.2 million in 2022, then slipped by 9.63% to -$87.9 million in 2023, then soared by 44.01% to -$49.2 million in 2024, then declined by 21.77% to -$59.9 million in 2025, then rose by 20.46% to -$47.7 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$47.7 million, -$59.9 million, and -$42.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison